Beneath the Label - Evaluating the FDA Approval of Copenhagen Classic Snuff as a Modified Risk Tobacco Product

Authors

Yisroel Grabie, Staten Island University HospitalFollow
Tafani Chowdhury, Hofstra UniversityFollow
Sudeep Acharya, Staten Island University HospitalFollow

Keywords

tobacco; smokeless; snuff; nasal tobacco; nose neoplasms; nasal cancer; nasopharyngeal neoplasms; tobacco use disorder

Disciplines

Food and Drug Law

Abstract

In this review, we critically evaluate the Food and Drug Administration's modified risk tobacco product (MRTP) status granted to a smokeless tobacco product (March 2023), Copenhagen Classic Snuff (CCS). This new status necessitates an assessment of the product CCS use and its public health impacts. We assess the impact of CCS as it relates to the reduction of lung cancer risk and the potential increased risk for nasopharyngeal cancer, chronic rhinitis, nicotine dependence, and other health hazards. Concerns persist regarding nicotine's harm and public misperception due to risk reclassification, and caution should be maintained to discourage novel snuff users. Advocating prudent interpretation of MRTP status and comprehensive post-market surveillance is necessary for critical assessment by health care professionals and consumers.

Recommended Citation

Grabie, Yisroel; Chowdhury, Tafani; and Acharya, Sudeep (2025) "Beneath the Label - Evaluating the FDA Approval of Copenhagen Classic Snuff as a Modified Risk Tobacco Product," HCA Healthcare Journal of Medicine: Vol. 6: Iss. 3, Article 1.
DOI: 10.36518/2689-0216.1832
Available at: https://scholarlycommons.hcahealthcare.com/hcahealthcarejournal/vol6/iss3/1